Anti-Inflammatory Scalp Actives: Salicylic Acid, Niacinamide & Centella — Regulatory Compliance Guide

Overview #

Scalp inflammation is not a cosmetic edge case. It is the underlying mechanism behind dandruff, seborrheic dermatitis, folliculitis, and a significant share of stress-related hair loss presentations. When brand partners brief us on scalp actives, the first question we ask is: which market are you launching in first? Because the regulatory answer for salicylic acid alone changes your formulation ceiling, your labeling copy, and your registration timeline — sometimes by 12 months. Niacinamide and Centella asiatica sit in a more comfortable position across markets, but they carry their own documentation burdens that catch brands off guard.

Salicylic Acid: Where the Regulatory Gaps Are Largest #

Salicylic acid is the most tightly regulated of the three actives in this article, and the gap between markets is wider than most brands expect.

Under EU Cosmetics Regulation 1223/2009, salicylic acid is listed in Annex III (entry 1) as a restricted substance. For rinse-off hair products, the permitted maximum is 3.0%. For leave-on scalp products — serums, tonics, overnight treatments — the limit drops to 2.0%. The EU also mandates a specific on-pack warning: “Contains Salicylic Acid. Not for use on children under 3 years of age.” That warning is non-negotiable and must appear in the language of the country of sale. We’ve had brand partners come to us with finished packaging artwork that omitted this line. That’s a recall risk.

The FDA Cosmetics Guidelines take a different approach. Salicylic acid in OTC anti-dandruff shampoos is regulated as an active drug ingredient under the OTC Drug Monograph system, permitted at 1.8%–3.0% in rinse-off formats. If you’re positioning a leave-on scalp serum as purely cosmetic — no dandruff claim — the FDA doesn’t set a hard concentration ceiling the way the EU does, but your safety substantiation needs to be airtight. The moment you make a dandruff or seborrheic dermatitis claim, you’re in drug territory and the documentation burden multiplies.

China’s NMPA Cosmetic Regulation classifies salicylic acid as a restricted ingredient under the 2021 Cosmetic Supervision and Administration Regulation (CSAR). The permitted limit is 2.0% for rinse-off products and 0.5% for leave-on products. That 0.5% ceiling for leave-on formats is the tightest of the three major markets and is the single most common formulation constraint we encounter when brands want to launch a leave-on scalp treatment in China simultaneously with their EU or US launch. You cannot use the same formula. Full stop.

One failure mode we see repeatedly: brands approve a 1.5% salicylic acid leave-on scalp serum for EU and US, then assume China registration is a paperwork exercise. It isn’t. The formula has to be reformulated to ≤0.5%, which changes the efficacy profile, which sometimes changes the clinical data package, which adds 3–4 months to the timeline.

The EU notification via CPNP is relatively fast — typically 2–4 weeks once your safety assessment is complete. China is the long pole. A new ordinary cosmetic filing under CSAR takes 3–5 months on average in our experience, and if NMPA requests supplementary data, add another 2–3 months. We now tell brand partners to budget 9 months for China launch from brief sign-off, not 6.

Niacinamide: The Easier Active That Still Has Traps #

Niacinamide doesn’t carry the same cross-market restriction complexity as salicylic acid. Neither the EU, FDA, nor NMPA impose a hard concentration ceiling for niacinamide in cosmetics. In practice, scalp formulations run between 2% and 5% for anti-inflammatory positioning, and up to 10% in some brightening or sebum-control scalp serums.

That said, the regulatory traps are real — they’re just different.

In the EU, niacinamide at higher concentrations (above 4–5%) can trigger flushing in some consumers, particularly in leave-on formats with occlusive delivery. This isn’t a regulatory limit, but it is a safety assessment flag. Your SCCS Scientific Opinion review process will flag consumer exposure calculations at high concentrations, and your Cosmetic Product Safety Report (CPSR) author needs to address it explicitly. We’ve seen CPSRs rejected by EU Responsible Persons because the assessor didn’t account for scalp leave-on exposure in the systemic absorption calculation.

For China, niacinamide is a standard cosmetic ingredient with no special filing requirements at typical use levels. The documentation burden is straightforward. Where brands get into trouble is when they combine niacinamide with salicylic acid in a leave-on scalp product and try to make both a brightening claim and an anti-dandruff-adjacent claim. NMPA reads claims carefully. Functional claims drive classification, and classification drives whether you’re in ordinary cosmetic filing or special-use registration — which is a completely different timeline and cost structure.

The clinical evidence for niacinamide in scalp inflammation is reasonably solid. One double-blind, randomized controlled trial (n=44, 12 weeks) demonstrated a 34% reduction in scalp erythema scores and a 28% reduction in sebum excretion rate in subjects using a 4% niacinamide leave-on scalp tonic versus vehicle control. What that study doesn’t capture — and what we observe in our own stability and consumer testing — is the interaction effect with pH. Niacinamide hydrolyzes to nicotinic acid at low pH, which is exactly the condition you create when you combine it with salicylic acid in an acidic scalp serum. At pH below 4.0, we see measurable niacinamide degradation within 8 weeks at 40°C. We now formulate niacinamide-salicylic acid combinations at pH 4.2–4.8 as a minimum, and we run 12-week accelerated stability as standard before any submission package goes out.

Centella Asiatica: The Regulatory Comfort Zone With a Standardization Problem #

Centella is the most regulatory-friendly of the three actives across all major markets. It’s not restricted in the EU, not regulated as a drug ingredient by the FDA, and sits comfortably in ordinary cosmetic filing territory in China. Brands love it. We understand why.

The problem isn’t regulatory. It’s standardization.

Centella asiatica extracts vary enormously in their asiaticoside, madecassoside, and asiatic acid content depending on supplier, extraction method, and plant origin. We’ve tested incoming raw materials from five different suppliers against the same spec sheet and seen asiaticoside content range from 8% to 41% in what were all labeled as “40% total triterpenes” extracts. That’s not a regulatory issue — it’s a raw material quality issue that directly affects your efficacy claims and your batch-to-batch consistency.

When brand partners want to make a specific soothing or anti-inflammatory claim backed by clinical data, we push them toward standardized TECA (Titrated Extract of Centella Asiatica) or defined-ratio triterpene blends rather than generic Centella extract. The cost difference is real — standardized TECA runs roughly 2.5–3× the price of commodity Centella extract — but the claim substantiation is cleaner and the stability profile is more predictable.

For EU safety assessments, Centella extracts need to be characterized in the CPSR with their full compositional profile. “Centella asiatica extract” as a single line item is not sufficient for a rigorous CPSR. We require suppliers to provide full triterpene assay data, heavy metal testing, and pesticide residue certificates before we’ll include any Centella material in a submission package.

In China, Centella asiatica is listed in the INCI inventory and requires no special documentation beyond standard ingredient safety data. Honestly, it’s one of the cleaner ingredients to work with from a China filing perspective. The complexity comes when brands want to make specific functional claims — “reduces scalp inflammation by X%” — because then you need clinical substantiation that NMPA can review, and the quality of that data matters.

Where Most Brands Get This Wrong #

The combination formula is where projects go sideways most often.

Brands come to us wanting a single leave-on scalp serum with salicylic acid for exfoliation, niacinamide for sebum control and anti-inflammation, and Centella for soothing. On paper, that’s a logical brief. In practice, you’re trying to satisfy three different regulatory ceilings across three markets simultaneously, manage pH-driven stability interactions between two of the actives, and build a claims package that doesn’t accidentally trigger drug classification in any jurisdiction.

We’ve run this combination at 2% salicylic acid / 4% niacinamide / 1% Centella TECA in a leave-on serum at pH 4.5. It works in the EU and US. It fails China’s leave-on salicylic acid limit immediately. The reformulated China version at 0.5% salicylic acid has a meaningfully different exfoliation profile, which means the clinical data from the EU/US version doesn’t fully transfer. You’re essentially running two development tracks.

The other failure mode is preservative system interaction. At pH 4.2–4.5, phenoxyethanol and ethylhexylglycerin perform well. But when brands push for “clean” preservative systems — organic acids, ferment-based systems — the efficacy window narrows significantly. We ran a pilot batch of a Centella-niacinamide scalp tonic with a leuconostoc ferment filtrate preservative system at pH 4.8. Passed challenge testing at lab scale (500g). At 50kg production scale, we had gram-positive contamination at week 6 of preservation challenge testing. The mixing dynamics at scale changed the effective distribution of the preservative. We went back to a low-level phenoxyethanol system at 0.5% and it’s been clean since. That’s not a story we tell to scare brands away from clean formulation — it’s a story we tell so they understand why we ask for 4 extra weeks on scale-up validation.

Regulatory timelines also interact in ways brands don’t anticipate. ICH Stability Guidelines provide the framework we use for accelerated stability design — 40°C/75% RH for 6 months minimum — but NMPA has its own stability requirements that don’t map perfectly onto ICH Q1A. For scalp products with active claims, NMPA expects stability data under conditions that reflect Chinese climate zones, which means 30°C/65% RH long-term data in addition to accelerated. That adds time.

Formulation Notes for Brand Partners #

What market? What are you expecting on-pack? Those are the first two questions we ask in every brief intake call, and the answers determine everything downstream.

If you’re launching EU-first with a leave-on scalp serum, we can work with salicylic acid up to 2.0%, niacinamide up to 5%, and Centella TECA at 0.5–1.0% in a pH 4.2–4.8 system. Your CPSR needs to be commissioned early — we recommend briefing your EU Responsible Person at the same time you brief us, not after formula lock. Budget 16–20 weeks from brief to CPNP notification submission.

If China is in scope, even as a phase-two market, tell us at brief stage. The salicylic acid ceiling at 0.5% leave-on means we design a separate China SKU from day one rather than retrofitting later. China NMPA filing for an ordinary cosmetic with active ingredients typically runs 4–6 months from complete dossier submission, and we’ve seen it stretch to 9 months when supplementary data is requested.

For US MoCRA compliance, cosmetic product facility registration and product listing are now mandatory under the Modernization of Cosmetics Regulation Act. If you’re selling into the US, this is not optional. We prepare the ingredient listing data and support your US Responsible Person with the technical file, but the registration itself sits with the brand.

Our standard documentation package for a three-market scalp active launch includes: full formula disclosure with INCI and function, raw material safety data sheets, stability data (accelerated + real-time), challenge test results, CPSR-ready technical dossier, NMPA ingredient safety summaries, and claims substantiation summary. We also flag any ingredients that require pre-market notification or special handling in each jurisdiction. It’s not a light package. But it’s what you need to actually get to shelf.

For deeper background on our approach to acid exfoliation technology and barrier repair formulation for sensitive skin, those pages cover the underlying formulation science that informs how we approach scalp active systems.

Frequently Asked Questions #

Q: We want 2% salicylic acid in a leave-on scalp serum — can we sell that in China?

No. China’s NMPA limits leave-on salicylic acid to 0.5%. You’d need a separate China formula. We design both SKUs in parallel from brief stage so you’re not rebuilding the China version six months later.

Q: How long does China NMPA filing take for a scalp serum with these actives?

Budget 5–7 months from complete dossier submission for an ordinary cosmetic filing. If NMPA issues a supplementary data request — which happens on roughly 30–40% of filings with active ingredient combinations in our experience — add another 2–3 months. Start early.

Q: Can we combine salicylic acid and niacinamide in the same formula?

Yes, but pH management is critical. Below pH 4.0, niacinamide degrades measurably within 8 weeks at 40°C. We formulate these combinations at pH 4.2–4.8 minimum and run 12-week accelerated stability before any submission package. Don’t skip that step.

Q: Does Centella asiatica need special registration in any of the three markets?

Not as a restricted or special-use ingredient in EU, US, or China at typical cosmetic use levels. The documentation burden is standard. What matters is raw material standardization — we require full triterpene assay data from suppliers because “Centella extract” without characterization is not sufficient for a rigorous EU CPSR.

Q: What’s the minimum order quantity for a scalp serum with these three actives?

Our standard MOQ for a leave-on scalp serum with salicylic acid, niacinamide, and Centella TECA is 3,000 units. Below that, the cost-per-unit impact of the standardized TECA and the airless pump packaging — which adds roughly $0.50–0.70 per unit at this MOQ — makes the economics difficult for most indie brands. We can discuss fill-and-finish options for smaller initial runs.

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.